Federal Judge Reiterates Expanded Safe-Harbor Protections for Generics

A federal judge again dismissed Momenta Pharmaceuticals’ patent infringement claims against Teva and Amphastar, reiterating that the Hatch-Waxman Act’s safe-harbor provision extends to generic drugmakers’ use of patented inventions during both pre- and post-approval activities.
Washington Drug Letter